Companies › BioTheraVision
1 active drug program in 3 registered trials: 3 Phase 2; Ophthalmology.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| BTV100 Low dose (1% Cevimeline Ophthalmic Solution) M3 muscarinic receptor agonist | M3 | Phase 2 | Dry Eye | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06543303 | BTV100 Low dose (1% Cevimeline Ophthalmic Solution) | Phase 2 | Dry Eye | Ophthalmology | Jan 2026 |
| NCT06543303 | BTV100 Low dose (1% Cevimeline Ophthalmic Solution) | Phase 2 | Dry Eye | Ophthalmology | Jan 2026 |
| NCT06543303 | BTV100 Low dose (1% Cevimeline Ophthalmic Solution) | Phase 2 | Dry Eye | Ophthalmology | Jan 2026 |
Qlaris Bio Aperta Biosciences Jiangsu Jingze Biopharmaceutical ONL Therapeutics Vantage Biosciences
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.